Skip to main content
Trending
Corporate earningsAi infrastructureEnergy marketsElection litigationAviation safetyCrypto securityAi governanceEnterprise aiPlatform liabilityAvian influenzaClinical trialsFederal debtPresidential runoffRpg developmentSpace debrisAir defenseAutonomous vehiclesBudget crisisBug bountiesEnergy m&aForeign investmentFranchise restructuringGene therapyPandemic treatyTranslation pathwaysUn peacekeepingWeapons testingWeight-space programmingAi copyright lawArchaeological toxicology

full timeline

AbbVie's Tavapadon Eases Parkinson's Motor Symptoms Without Severe Side Effects

The U.S. Food and Drug Administration has authorized AbbVie's JUVMO, a targeted once-daily tablet that preserves motor control while avoiding the severe side effects of older dopamine therapies.

Factlen Newsroom· Updated

Follow AbbVie's Tavapadon Eases Parkinson's Motor Symptoms Without Severe Side Effects in the Factlen app and get an alert when there is news. Get the app

The FDA has approved AbbVie's JUVMO, marking the first new class of Parkinson's medication in decades.From: FDA Approves JUVMO, Marking First New Class of Parkinson's Drug in Decades

Share this story

Key numbers

9.7 points
Reduction in motor symptom severity score
1.1 hours
Increase in daily 'ON' time without troublesome dyskinesia
10 million
People living with Parkinson's globally

From: AbbVie's Tavapadon Eases Parkinson's Motor Symptoms Without Severe Side Effects

Charts, maps and images

Patients taking JUVMO demonstrated significant improvements in motor and daily-living scores compared to placebo over 26 weeks.From: FDA Approves JUVMO, Marking First New Class of Parkinson's Drug in Decades ·
Phase 3 trials demonstrated a significant reduction in motor symptom severity for early-stage patients.From: AbbVie's Tavapadon Eases Parkinson's Motor Symptoms Without Severe Side Effects ·
By selectively targeting D1 and D5 receptors, tavapadon avoids the pathways that trigger severe behavioral side effects.From: AbbVie's Tavapadon Eases Parkinson's Motor Symptoms Without Severe Side Effects ·
Tavapadon's targeted mechanism resulted in significantly lower rates of sleep attacks and compulsive behaviors.From: AbbVie's Tavapadon Eases Parkinson's Motor Symptoms Without Severe Side Effects ·
The new medication offers neurologists a targeted tool to delay levodopa escalation in early-stage patients.From: FDA Approves JUVMO, Marking First New Class of Parkinson's Drug in Decades ·
If approved, the drug will give neurologists a new tool to delay the onset of debilitating motor fluctuations.From: AbbVie's Tavapadon Eases Parkinson's Motor Symptoms Without Severe Side Effects ·

Timeline

September 2026

  1. FDA Approves JUVMO, Marking First New Class of Parkinson's Drug in Decades

July 2026

  1. AbbVie's Tavapadon Eases Parkinson's Motor Symptoms Without Severe Side Effects